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Background: The mechanism by which mutant cartilage oligomeric matrix protein (COMP) induces a pseudoachondroplasia 
phenotype remains unknown, and the reason why a mutation of a minor protein of the growth plate cartilage causes total 
disruption of endochondral bone formation has not yet been determined. The current study was performed to investigate 
the effects of mutated COMP on the synthesis of the cartilage-specific major matrix proteins of Swarm rat chondrosarcoma 
chondrocytes.
Methods: The Swarm rat chondrosarcoma chondrocytes transfected with a chimeric construct, which consisted of a mutant gene 
of human COMP and an amino acid FLAG tag sequence, were cultured in agarose gel. Formation of extracellular proteoglycan and 
type-II collagen by the cells was evaluated by immunohistochemical staining and measuring the 
35S-sulfate incorporation.
Results: No difference was observed for the detection of type-II collagen among the cell lines expressing mutant COMP and the 
control cell lines. Histochemical staining of sulfated proteoglycans with safranin-O showed that lesser amounts of proteoglycans were 
incorporated into the extracellular matrix of the chondrocytes transfected with the mutant gene. 
35S-sulfate incorporation into the cell/
matrix fractions demonstrated markedly lower radiolabel incorporation, as compared to that of the control cells.
Conclusions: Mutation of COMP has an important impact on the processing of proteoglycans, rather than type-II collagen, in the 
three-dimensional culture of Swarm rat chondrosarcoma chondrocytes.
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Longitudinal bone growth is controlled by endochondral 
ossification and this requires smooth orchestration of 
chondrocytes proliferation, cellular differentiation and 
the formation of the extracellular matrix (ECM) in the 
growth plate. Mutations in many different ECM protein 
genes can interfere with this orchestration and disrupt 
normal skeletal growth.
1-3) Among them, cartilage olig-
omeric matrix protein (COMP) has been identified as 
the abnormal protein in two types of human autosomal 
dominant skeletal dysplasias: pseudoachondroplasia 
(PSACH) and multiple epiphyseal dysplasia.
4,5) Th  e  tissue 
pathology of the growth plate cartilage is striking in 
patients with PSACH. Electron microscopy has shown 
marked dilatation of the rough endoplasmic reticulum 
(rER) of those chondrocytes with COMP retained in 
them.
6-8) 
COMP is a 524-kDa homopentameric extracellular 
matrix protein that consists of 737 amino acid monomeric 
units linked through the interchain disulfide bonds at 182
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Csy49 and Cys52. Th   e single gene copy is coded from 19 
exons that have strong sequence homology within exons 
4-19 to four other known thrombospondin genes (exons 
11-22).
9) Most of the mutations in PSACH have been 
identifi  ed in the highly conserved type-3 repeat calcium-
binding domain that is encoded by exons 13C to 18A. 
Previous studies have shown that the COMP that harbors 
mutations within the type-3 repeat binds to half the 
number of Ca
2+ ions compared to the wild type protein,
9,10) 
and that the wild and mutant type proteins show diff  erent 
conformations in the presence of calcium.
9) Th  ese  fi  ndings 
suggest that mutation specifi  cally aff  ects COMP processing 
by impeding the normal protein folding that is needed for 
its secretion from the rER.
As a minor extracellular matrix protein, COMP 
was originally identified in cartilage
11,12) and it has been 
since been identified in the cells of ligaments and ten-
dons.
8,13) According to the electron microscopic fi  ndings, 
retention of COMP in patients with PSACH is specifi  c to 
chondrocytes. However, a monolayer culture of PSACH 
chondrocytes has shown cellular dedifferentiation to a 
fibroblast-like phenotype and disappearance of the in-
tracellular retention of COMP.
14) Furthermore, the inability 
to distinguish mutant human COMP (hCOMP) from the 
wild type being expressed in PSACH chondrocytes, and 
the lack of the expression of mutant hCOMP to generate 
a PSACH phenotype in any cells other than chondrocytes 
have hampered the studies on monitoring the processing 
of mutant COMP and its eff  ect on the formation of other 
ECM molecules. 
The current study was undertaken to investigate 
the eff  ects of a mutant hCOMP on the secretion of carti-
lage-specific proteins such as proteoglycans and type-II 
collagen. A three-dimensional culture of chondrocytes 
transfected with a chimeric construct containing a mu-
tant hCOMP coupled with a FLAG tag sequence was 
utilized, and this readily permitted selective monitoring 
of the mutant hCOMPFLAG during the processing of rat 
endogenous COMP (rCOMP). 
METHODS
Th   ree-dimensional Agarose Cell Cultures
We used three clones that came about from the develop-
ment of stable transformed long-term culture (LTC) cell 
lines (a gift from Dr. J. W. Stevens of The University of 
Iowa).
6,9,14-16) The DNA vector constructs were originally 
transfected into the Swarm rat chondrosarcoma LTC 
cells
16) with using either lipofectin (Life Technologies, 
Grand Island, NY, USA) or SuperFect (Qiagen Inc, Valen-
cia, CA, USA) per the manufacturer’s procedure. Clone 
“C415” consisted of a DNA construct that express the 
PSACH-linked mutant COMP (deletion of aspartic 
acid 469) and an 8 amino acid FLAG tag sequence that 
was utilized for the immunodetection of the expressed 
mutant hCOMPFLAG with performing western blotting in a 
previous study (Fig. 1).
15) Clone “C422”, which contained 
an antisense sequence of the mutant hCOMP, was used 
Fig. 1. Construction of a mutant hCOMPFLAG 
chimeric protein. A primer set consisting 
of an oligonucleotide sequence that en-
compasses the transcription start site 
and an oligonucleotide containing the 3’ 
end of COMP with a mutation of the stop 
codon, plus a sequence that encodes for 
the 8 amino acid FLAG epitope was used 
to generate a 2348 nucleotide PCR product 
from the clone Mut3 that encodes for 
PSACH-linked ΔD469 hCOMP. The DNA 
fragment was inserted into the pcDNA 3.1 
expression vector following ligation into 
the pCR2 vector blunt to obtain the Eco RI 
DNA restriction enzyme sites.183
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as a transfectant negative control, and the LTC cells of the 
Swarm rat chondrosarcoma were used as a control cell 
line.
Three cell lines were individually cast in dialysis 
tubes (4 mm in diameter) at 5 × 10
6 cells/ml in a 1% 
low melt agarose-complete growth medium cell cul-
ture suspension. The castings were maintained in 
complete growth medium
16) that consisted of Dulbecco’s 
Modified Eagle’s Medium (4.5 gm glucose per liter), 
12% heat inactivated fetal bovine serum, 25 mM N-2-
hydroxyethylpiperazine-N’-2-ethane sulfonic acid, 
ascorbic acid 50 μg/ml and gentamycin 50 μg/ml. The 
growth medium was changed daily.
35S Incorporation Assay
Three sections of the castings (0.5-1 cm in length) were 
removed per cell line and these were cultured with 
35S-H2SO4 at 50 μCi/ml in growth medium for 24 hours 
prior to harvesting at days 1, 4, 7, 14 and 28. Following 
washing and removing the unincorporated radiolabel, 
the castings were frozen in Tissue Freezing Medium 
(Triangle Biomedical Science, Durham, NC, USA). Th  ir-
ty 10 μm sections cut on a cryomicrotome were taken 
from each casting (3 per cell line, per time point) with 
sections 1-5, 11-15 and 21-25 being pooled in microfuge 
tubes. Th   e pooled sections were melted at 72°C in 500 μl 
of papain solution (- 17 units/mg protein from papaya 
latex, Sigma-Aldrich, St Louis, MO, USA) at 0.1 mg/ml 
in 0.1 M sodium acetate (pH 6.5) and 5 mM mannitol. 
Sodium azide (0.025%, w/v) was added and then this was 
incubated at 60°C for 24 hours. Digest was applied to a 
Sepharose G-50 column (0.7 × 14 cm), equilibrated in 
papain digestion buffer, void column volume, devoid of 
unincorporated radiolabel, and was collected. Th  e  amount 
of radiolabel was determined in a liquid scintillation 
counter (Model LS380; Beckman, Fullerton, CA, USA) 
following the addition of 4 ml of Bio-Safe II counting 
cocktail (Research Products International Corp., Mount 
Prospect, IL, USA). Statistical analysis was performed by 
ANOVA.
Immunohistochemical Studies
To randomly analyze the sections, every 10th section was 
singularly analyzed starting with the fi  rst collected section, 
and each analysis was performed in triplicate. A series of 
sections was fi  xed in 10% neutral formalin and embedded 
in paraffin per the usual method. Five-micron sections 
were placed on gelatin-coated slides, deparaffinized 
with xylene and then hydrated with in a graded series of 
ethanol solutions. Th   e sections were washed with 20 mM 
sodium phosphate (pH 7.4) and 150 mM NaCl and the 
sections were treated with Target Unmasking Fluid (Signet 
Laboratories, Dedham, MA, USA) at 70°C for 20 minutes. 
Following two washes with 20 mM sodium phosphate 
(pH 7.4) and 0.15 M sodium chloride, the sections were 
treated with chondroitin ABC lyase (Seikagaku America, 
Rockville, MD, USA) at 0.25 units/ml and Streptomyces 
hyaluronidase (Calbiochem, La Jolla, CA, USA) at 0.625 
units/ml in 0.1 M Tris-HCl and 0.1 M sodium acetate (pH 
7.2) for 90 minutes at 37°C. 
The sections were washed three times with 20 
mM sodium phosphate (pH 7.4) and 150 mM NaCl for 
5 minutes each time, and the sections were then treated 
with 0.3% hydrogen peroxide in methanol for 30 minutes 
at room temperature, and then they were washed three 
times for 5 minutes each time. Th   e samples were blocked 
with 10% horse serum (for M2 antibody, Eastman Kodak 
Company, Scientific Imaging System, New Haven, CT, 
USA), 10% goat serum (for anti-ratCOMP antibody), 1% 
bovine serum albumin and 0.1% Tween-20 in 20 mM 
sodium phosphate (pH 7.4) and 150 mM NaCl at room 
temperature for 30 minutes. Th  e  FLAG epitope containing 
species were detected with M2 antibody at 1 μg/ml, 
while the total COMP (rat and human) was detected 
with a rabbit polyclonal antibody generated against the 
8 amino acid carboxyl terminus of rCOMP, which has 
62.5% homology to the human COMP carboxyl terminus 
sequence.
17) The samples were washed three times with 
20 mM sodium phosphate (pH 7.4) and 150 mM NaCl 
for 5 minutes each time. A series of sections was treated 
with murine monoclonal antibodies for II-II63B (type II 
collagen, gift from Dr. J. W. Stevens) and M2 antibody, 
and this was developed with DAB substrate following the 
addition of biotin-conjugated anti-murine IgG secondary 
antibody and horseradish-conjugated streptovavidin. 
Additionally, some sections were processed for safranin-O 
staining for identifying cartilage-specific sulfated glycos-
aminoglycans. 
RESULTS
Immunohistochemical staining of type II collagen, fol-
lowing the culture of the human mutant COMP cell line 
(C415) and the two control cell lines of C422 and LTC, 
showed that type II collagen was detected in all the cell 
lines at day 1, and an increase in staining intensity con-
tinued through day 7 with no apparent additional increase 
at day 14 or 28 thereaft  er. No diff  erences were observed for 
detecting type II collagen between the expressed mutant 
COMP cell line and those of the control cell lines (Fig. 184
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2). Immunodetection study of the mutant COMP-FLAG 
epitope following culture of the mutant hCOMPFLAG cell 
line C415 showed that mutant hCOMPFLAG was detected 
intracellularly at day 1 with a slight increase in intensity 
at day 4 (Fig. 3). FLAG positive staining was also detected 
in what appears to be the pericellular matrix of the cells, 
suggesting that a portion of the mutant COMP was se-
creted by the cells.
35S-sulfate incorporation at various times showed 
that identifi  able newly formed proteoglycans from all the 
cultured cells were seen through day 14 with the greatest 
amount being synthesized at days 4 and 7 (Fig. 4). For 
the four time points, the C415 cells incorporated from 
8.9 × 10
3 ± 2.3 × 10
3 to 16.5 × 10
3 ± 1.6 × 10
3 dpm per 5 
slices while the LTC cells incorporated from 12.2 × 10
3 
± 9.2 × 10
3 to 53.4 × 10
3 ± 0.1 × 10
3 dpm per 5 slices and 
the C422 cells incorporated from 31.1 × 10
3 ± 24.3 × 10
3 
to 98.6 × 10
3 ± 22.4 × 10
3 dpm per 5 slices. The C415 
cells that expressed the mutant hCOMPFLAG universally 
incorporated less radiolabeled sulfate than that of the C422 
and LTC control cell lines. Th   e C415 cells incorporated less 
radiolabeled sulfate compared to the hCOMP antisense 
C422 clone at days 4, 7 and 14 (17-24% less) and the LTC 
cells at day 7 (22% less) (p < 0.05). Undetected amounts 
of radiolabeled sulfate were incorporated into the cells at 
the 28 day time point (data not shown), suggesting a cell 
to ECM homeostatic equilibrium had been reached, as 
was reflected by a minimal degree of newly synthesized 
proteoglycans. 
Histochemical staining of the sulfated proteoglycans 
with safranin-O showed that lesser amounts of proteo-
glycans were incorporated into the extracellular matrix of 
the cells containing the mutant hCOMPFLAG transgene (Fig. 
5), suggesting that the expression of the mutant COMP 
reduces the deposition of aggrecan in the extracellular 
matrix.
DISCUSSION
In individuals with PSASH, their dramatically reduced 
limb lengthening appears to the result of an altered expan-
sion of the extracellular matrix and longitudinal growth 
of the chondrocytes prior to ossification.
17-20) Lamellar 
inclusion of the rER in the growth plate chondrocytes is 
the cytochemical hallmark for the PSACH phenotype, 
linking an endoplasmic reticulum storage disorder with 
Fig. 2. Immunohistochemical staining of type II collagen at day 14. No differences for type II collagen were observed between the expressed mutant 
COMP cell line (C415) (A) and that of the antisense transfectant control cell line (C422) (B) (×200).
Fig. 3. Immunohistochemical identification of human PSACH-linked 
mutant COMP tagged with a selective immunoreactive sequence that 
was distinct from that of rat COMP in the Swarm rat chondrosarcoma 
cells cultured for 14 days. Brown staining identifies the retention of 
expressed mutant COMP within the cells (×1,500).185
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the osteochondrodysplasia. A PSACH canine model sug-
gested that abatement of the cumulative vertical growth 
of the chondrocytes is caused by 1) altered extracellular 
matrix constraints for horizontal growth and 2) uncou-
pling of the endochondral and perichondral growth that 
causes metaphyseal fl  aring.
21) 
COMP is selectively expressed in the cells of car-
tilage, tendon, ligament and synovium. In the growth 
plate cartilage of PSACH individuals, COMP is localized 
to the electron-lucent lamellae of the rER, but the rERs 
of the tendon and ligament tissues are unaltered. Normal 
growth and development occurs in COMP gene knockout 
mice that do not synthesize COMP, demonstrating that 
a mutant COMP, not the absence of COMP, is required 
for the PSACH phenotype.
22) However, the mechanism 
by which mutant COMP induces a PSACH phenotype 
remains unknown, and the reason why a mutation of a 
minor protein of the growth plate cartilage causes total 
disruption of endochondral bone formation remains 
to be determined. The altered conformation of COMP 
induced by mutation has been proposed for the possible 
mechanism for COMP not being properly processed from 
the rER.
14) In patients with PSACH, COMP is retained 
intracellularly, but no direct evidence has demonstrated 
that a mutant COMP itself is responsible for its retention. 
Moreover, subtle amino acid differences of the mutant 
COMP, as compared with the wild type, preclude mon-
itoring the expression of the individual COMP species. 
The use of a PSACH-like cell culture system with 
Fig. 4. 
35S-sulfate incorporation into the cell/matrix fractions of the 
cell lines cultured in 1% agarose for varying times (Days 1, 4, 7, and 
14). The C415 cells expressing the mutant hCOMPFLAG, demonstrated 
markedly lower radiolabel incorporation compared to the C422 mutant 
hCOMPFLAG antisense control cells and the LTC cells. An asterisk indicates 
statistically signiﬁ  cant difference at p < 0.05, as compared to the C415 
cells.
Fig. 5. Histochemical staining of sulfated proteoglycans with safranin-O. 
Lesser amounts of proteoglycans are incorporated into the ECM in the 
C415 cell line (left panel) compared to the C422 cell line (right panel), 
suggesting the expression of the mutant COMP is altering the deposition 
of aggrecan in the ECM, as is similarly seen in PSACH patients (×200).
unlimited numbers of cells of the chondrosarcoma cell line 
permitted us to perform the manipulative experiments, 
which are impossible when using human tissue or isolated 
cells. Furthermore, the reason why we used a three-dimen-
sional culture of chondrosarcoma cells is that the cartilage 
formed during the monolayer culture of chondrocytes 
becomes increasingly fi  brous in nature when the cells are 
cultured for extended periods of time.
23)
The extracellular matrix of the growth plate car-
tilage functions as a template for future trabecular bone, 
and this consists of tissue fluids and a framework of 
structural macromolecules such as type-II collagen, pro-
teoglycans and non-collagenous proteins. The current 
study demonstrated that the expression of a PSACH-
linked mutant COMP in a rat chondrosarcoma cell line 
alters extracellular matrix formation with regard to 
incorporating proteoglycan into the extracellular matrix. 
This can be explained by the effects of mutant COMP 
on the post-translational processing of proteoglycans 
and the addition of the glycosaminoglycan chains in the 
Golgi apparatus. However, we think that this is not a gen-
eral defect in the protein processing. For example, the 
secretion of cartilage-specific type-II collagen was found 
to be unaltered for its pericellular site distribution relative 
to the control cell lines. 
Our data imply that the defect affects a subset of 
extracellular matrix molecules that includes proteoglycans, 
and that mutant COMP selectively alters the incorporation 
of proteoglycan molecules into the ECM. Secretory pro-186
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